結直腸癌
結直腸癌是一種起源于結腸或直腸粘膜上皮細胞的惡性腫瘤,其發病率在全球范圍內居高不下,是導致癌癥相關死亡的主要原因之一。根據腫瘤的位置,結直腸癌可以分為結腸癌和直腸癌。結腸癌通常起源于結腸的息肉,而直腸癌則多發生在直腸的下段。結直腸癌的癥狀包括便血、排便習慣改變、腹痛、體重下降等。
結直腸癌的治療已經從傳統的化療藥物發展到針對特定分子靶點的靶向治療和免疫治療。以下是一些重要的藥物靶點及其相關藥物的研發進展:
- EGFR (表皮生長因子受體):在約10%的結直腸癌中過度表達,針對EGFR的單克隆抗體如西妥昔單抗已被用于治療某些類型的結直腸癌。
- RAS (KRAS和NRAS):RAS基因突變在結直腸癌中較為常見,尤其是KRAS突變。近年來,針對KRAS G12C突變的抑制劑如索托拉西布(Sotorasib, AMG510)取得了突破性進展,為攜帶此突變的患者提供了新的治療選擇。
- BRAF:BRAF V600E突變是結直腸癌中另一個重要的治療靶點。BRAF抑制劑如維莫非尼(Vemurafenib)和MEK抑制劑如考比替尼(Cobimetinib)的聯合使用,已經在治療BRAF突變的晚期結直腸癌中顯示出較好的療效2。
- HER2 (人表皮生長因子受體2):HER2過表達在一部分結直腸癌患者中出現,針對HER2的靶向治療如圖卡替尼(Tucatinib)聯合曲妥珠單抗(Trastuzumab)已經獲得FDA批準,用于治療HER2陽性的晚期結直腸癌患者。
- MSI (微衛星不穩定性):MSI-H或dMMR (錯配修復缺陷)的結直腸癌對免疫治療有較好的反應。免疫檢查點抑制劑如帕博利珠單抗(Pembrolizumab)在這類患者中已經顯示出顯著的療效。
- VEGF (血管內皮生長因子):抗VEGF單抗如貝伐珠單抗(Bevacizumab)通過抑制腫瘤血管生成,已經被廣泛應用于晚期結直腸癌的治療。
結直腸癌藥物靶點
結直腸癌藥物靶點相關產品推薦
● 靶點蛋白
CSB-MP007479HU

Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
CSB-MP619964HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP009705HU(M)

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP007763HU

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP878942HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP005165HU

Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM5 at 2μg/mL can bind Anti-CEACAM5 recombinant antibody (CSB-RA005165MA1HU), the EC50 is 0.8955-1.719 ng/mL.
CSB-MP011649HU3

Measured by its binding ability in a functional ELISA. Immobilized Human IL2RA at 2μg/mL can bind Anti-IL2RA recombinant antibody (CSB-RA011649MA1HU),the EC50 is 2.463-3.353 ng/mL.
CSB-MP023997HU1

Measured by its binding ability in a functional ELISA. Immobilized TNFSF9 at 2 μg/ml can bind TNFRSF9(CSB-MP023984HU1), the EC50 is 2.671-3.702 ng/mL
● 重組抗體
CSB-RA878942MA1HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA878942MA1HU (red line) at 1:100.
CSB-RA005165MA3HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA005165MA3HU (red line) at 1:100.
CSB-RA159341A0HU

Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
CSB-RA011087MA1HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA011087MA1HU (red line) at 1:50.
產品名稱 | 貨號 | 靶點 | 反應種屬 | 應用范圍 |
---|---|---|---|---|
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody | CSB-RA007479A1092phHU | EGFR | Human | ELISA, WB |
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody | CSB-RA007479A1068phHU | EGFR | Human | ELISA, WB |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341A0HU | EGFR | Human | ELISA, WB, IHC, IF, FC |
EGFR Recombinant Monoclonal Antibody | CSB-RA794061A0HU | EGFR | Human | ELISA, WB, IHC |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341MA1HU | EGFR | Human | ELISA, IHC, FC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA932207A0HU | EPCAM | Human | ELISA, WB |
EPCAM Recombinant Monoclonal Antibody | CSB-RA439934A0HU | EPCAM | Human | ELISA, WB, IHC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA007717MA1HU | EPCAM | Human | ELISA, IHC, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
ERBB3 Recombinant Monoclonal Antibody | CSB-RA937008A0HU | ERBB3 | Human | ELISA, IF |
IGF1R Recombinant Monoclonal Antibody | CSB-RA011087MA1HU | IGF1R | Human | ELISA, FC |
IL2RA Recombinant Monoclonal Antibody | CSB-RA011649MA1HU | IL2RA | Human | ELISA, IF |
MET Recombinant Monoclonal Antibody | CSB-RA983271A0HU | MET | Human | ELISA, WB, IHC, IF, FC |
MET Recombinant Monoclonal Antibody | CSB-RA634199A0HU | MET | Human | ELISA, IHC |
MET Recombinant Monoclonal Antibody | CSB-RA013714MA1HU | MET | Human | ELISA, IF, FC |
NT5E Recombinant Monoclonal Antibody | CSB-RA978310A0HU | NT5E | Human | ELISA, IHC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |